Issue Navigation
-
Policy Forum
-
139-143
Access to orphan drugs in the Middle East: Challenge and perspective.
Almalki ZS, Alahmari AK, Guo JJ, Kelton CML
Intractable Rare Dis Res. 2012; 1(4):139-143.
DOI: 10.5582/irdr.2012.v1.4.139
-
144-150
Asakawa T, Fang H, Hong Z, Sugiyama K, Nozaki T, Namba H
Intractable Rare Dis Res. 2012; 1(4):144-150.
DOI: 10.5582/irdr.2012.v1.4.144
-
151-156
Classification and management of hepatolithiasis: A high-volume, single-center's experience.
Feng XB, Zheng SG, Xia F, Ma KS, Wang SG, Bie P, Dong JH
Intractable Rare Dis Res. 2012; 1(4):151-156.
DOI: 10.5582/irdr.2012.v1.4.151
-
157-160
Wu D, Hou QF, Li T, Chu Y, Guo QN, Kang B, Liao SX
Intractable Rare Dis Res. 2012; 1(4):157-160.
DOI: 10.5582/irdr.2012.v1.4.157
-
161-166
Study and analysis of the state of rare disease research in Shandong Province, China.
Zhao H, Cui YZ, Zhou XY, Pang JX, Zhang XM, Xu SQ, Han JX
Intractable Rare Dis Res. 2012; 1(4):161-166.
DOI: 10.5582/irdr.2012.v1.4.161
-
167-169
Dong QL, Cao SS, Zhang HW, Geng H
Intractable Rare Dis Res. 2012; 1(4):167-169.
DOI: 10.5582/irdr.2012.v1.4.167
-
170-171
-
172-174